PYC THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.105 AUD | +5.00% |
|
+10.53% | -4.55% |
| May. 16 | PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5% | MT |
| May. 09 | Transcript : PYC Therapeutics Limited - Special Call |
Presenter SpeechKaggen Ausma (Executives)So welcome, everyone, to the PYC August quarterly cal...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.105
AUD
Average target price
0.2933
AUD
Spread / Average Target
+179.36%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.55% | 312M | |
| +43.43% | 54.04B | |
| +43.57% | 41.96B | |
| -1.21% | 41.92B | |
| -7.59% | 28.35B | |
| +11.98% | 26.35B | |
| -21.85% | 19B | |
| +7.75% | 13B | |
| +29.16% | 12.28B | |
| +25.52% | 12.19B |
- Stock Market
- Equities
- PYC Stock
- News PYC Therapeutics Limited
- Transcript : PYC Therapeutics Limited - Special Call